Neurocrine announced that a new analysis of INGREZZA capsules, published in the Journal of Affective Disorders, demonstrated sustained improvement in tardive dyskinesia symptoms in patients with primary mood disorders. In the post-hoc analysis, INGREZZA significantly reduced involuntary movements associated with TD in patients with a primary mood disorder, such as bipolar and major depressive disorder, and was generally well tolerated with no clinically meaningful changes to psychiatric stability. INGREZZA is the first U.S. FDA approved treatment for adults with TD, a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.